中山醫學大學機構典藏 CSMUIR:Item 310902500/23517
English  |  正體中文  |  简体中文  |  全文笔数/总笔数 : 17939/22958 (78%)
造访人次 : 7388385      在线人数 : 119
RC Version 7.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
搜寻范围 查询小技巧：
  • 您可在西文检索词汇前后加上"双引号"，以获取较精准的检索结果
  • 若欲以作者姓名搜寻，建议至进阶搜寻限定作者字段，可获得较完整数据
    •  进阶搜寻


    jsp.display-item.identifier=請使用永久網址來引用或連結此文件: https://ir.csmu.edu.tw:8080/ir/handle/310902500/23517


    题名: Hepatitis C virus reinfection in patients on haemodialysis after achieving sustained virologic response with antiviral treatment
    作者: Liu, CH;Peng, CY;Kao, WY;Yang, SS;Shih, YL;Lin, CL;Tsai, MK;Lee, CY;Chang, CC;Wu, JH;Liu, CJ;Su, TH;Tseng, TC;Chen, PJ;Kao, JH
    日期: 2021
    上传时间: 2022-08-05T09:38:33Z (UTC)
    出版者: WILEY
    ISSN: 0269-2813
    摘要: Background Data are limited regarding the risk of hepatitis C virus (HCV) reinfection after treatment-induced sustained virologic response (SVR) in patients on haemodialysis. Aims To assess the risk of HCV reinfection among patients on haemodialysis with treatment-induced SVR. Methods Patients on haemodialysis patients who achieved SVR12 with interferon (IFN) or direct-acting antiviral (DAA)-based treatment received follow-up at SVR24 and then biannually with HCV RNA measurements. HCV reinfection was defined as the resurgence of viremia by different viral strains beyond SVR12. The low-risk general population who achieved SVR12 and who underwent the same post-SVR12 surveillance served as the reference group. Crude reinfection rates per 100 person-years (PYs) were calculated. Multivariate Cox regression analysis was performed to estimate the relative risk of HCV reinfection between the two groups. Results We recruited 374 patients on haemodialysis and 1571 reference patients with a mean post-SVR12 follow-up of 4.7 and 6.1 years. All haemodialysis patients who achieved SVR12 also achieved SVR24. The incidence rates of HCV reinfection were 0.23 per 100 PYs (95% confidence interval [CI]: 0.09-0.59) in haemodialysis patients and 0.16 per 100 PYs (95% CI: 0.10-0.26) in the reference group. The risk of HCV reinfection in patients on haemodialysis was comparable to that in the reference patients (hazard ratio [HR]: 1.39; 95% CI: 0.44-4.38, P = 0.57). Conclusions The risk of HCV reinfection in patients on haemodialysis who achieve SVR12 is low and comparable to that in the low-risk general population. HCV microelimination in this special population is feasible once universal screening and scaled-up treatment are implemented.
    URI: http://dx.doi.org/10.1111/apt.16697
    https://www.webofscience.com/wos/woscc/full-record/WOS:000717941000001
    https://ir.csmu.edu.tw:8080/handle/310902500/23517
    關聯: ALIMENTARY PHARMACOLOGY & THERAPEUTICS ,2022,v55,issue 4, P434-445
    显示于类别:[中山醫學大學研究成果] 期刊論文

    文件中的档案:

    档案 描述 大小格式浏览次数
    index.html0KbHTML197检视/开启


    SFX Query

    在CSMUIR中所有的数据项都受到原著作权保护.

    TAIR相关文章

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回馈